Balloon Aortic Valvuloplasty Might Be a Safe Therapeutic Option for Acute Decompensated Heart Failure Due to Severe Aortic Valve Stenosis

2017 ◽  
Vol 23 (10) ◽  
pp. S22 ◽  
Author(s):  
Saaya Fuda ◽  
Tsuyoshi Takada ◽  
Hiroki Saito ◽  
Hiroyuki Satake ◽  
Hironori Kanemitsu ◽  
...  
Keyword(s):  
Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Stenosis ◽  
Acute Decompensated Heart Failure ◽  
Therapeutic Option ◽  
Decompensated Heart Failure ◽  
Balloon Aortic Valvuloplasty ◽  
Aortic Valvuloplasty

scholarly journals Balloon valvuloplasty in two dogs with aortic valve stenosis showing congestive heart failure

2020 ◽  
Vol 65 (No. 2) ◽  
pp. 89-94
Author(s):  
T Yoshida ◽  
K Matsuura ◽  
S Goya ◽  
D Ma ◽  
K Shimada ◽  
...  
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Aortic Valve ◽  
Aortic Valve Stenosis ◽  
Clinical Symptoms ◽  
Aortic Flow ◽  
Balloon Valvuloplasty ◽  
Balloon Aortic Valvuloplasty ◽  
Aortic Valvuloplasty ◽  
Key Factor

A 10-year-old female Papillon and a 1-year-old male Golden Retriever were presented to the Tokyo University of Agriculture and Technology for a second opinion on an aortic valve stenosis (AS). The aortic flow rate was not as high as it should have been (the aortic flow velocity for case 1 and case 2 was 2.82 m/s and 3.96 m/s, respectively). However, the AS was suspected to be an exacerbating factor in the congestive heart failure, so that a balloon valvuloplasty was conducted. As a result, the congestion and clinical symptoms were much improved in both cases. In conclusion, in cases with an AS, in which afterload is a key factor for the exacerbation of the congestion, a balloon aortic valvuloplasty may reduce the afterload and consequently lead to an improvement in the congestion.

Abstract 19440: Reintervention Rates Following Balloon Aortic Valvuloplasty versus Surgical Valve Repair in Isolated Congenital Aortic Valve Stenosis - A Meta-analysis

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
May T Saung ◽  
Courtney McCracken ◽  
Ritu Sachdeva ◽  
Christopher J Petit
Keyword(s):  
Aortic Valve ◽  
Aortic Stenosis ◽  
Aortic Valve Stenosis ◽  
Meta Analysis ◽  
Valve Repair ◽  
Balloon Aortic Valvuloplasty ◽  
Congenital Aortic Stenosis ◽  
Primary Indication ◽  
Aortic Valvuloplasty

Introduction: The optimal treatment for congenital aortic stenosis (AS) is debated despite decades of experience with both balloon aortic valvuloplasty (BAV) and surgical aortic valve repair (SAV). While BAV has been the mainstay of therapy for AS, recent single-center reports suggest optimal results following SAV. Hypothesis: We propose that reintervention rates following SAV and BAV are equivalent. Methods: We queried Medline, EMBASE and Web of Science for eligible studies using the keywords: “congenital aortic stenosis”, “balloon valvotomy”, “aortic valve stenosis surgery” and “treatment outcome or reintervention”. Studies were excluded when cohort size was <20 pts, when follow-up was < 2.5 yrs from primary intervention, and when primary indication was not AS (e.g. SAV in the setting of aortic valve regurgitation (AR)). Outcomes analyzed included death, reintervention and moderate or severe AR. Analysis was performed using Comprehensive Meta Analysis v3 using random effects models. Results: A total of 20 studies were included in our meta-analysis: SAV alone (n=3), BAV alone (n=12), and both (n=5). The mean age at BAV was 3.1 years (range, 4 days - 7 years) with a mean follow-up duration of 6.8 years, while mean age at SAV was 2.8 years (range, 14.2 days - 7.1 years) with a mean follow-up duration of 9.1 years. Mortality rates following BAV and SAV were 12.3% (95% CI: 7.7 - 19.1) and 10.2% (95% CI: 7.0 - 14.5), respectively (p=0.27). Reintervention following initial procedure for treatment of AS was higher following BAV (35.7% [95% CI: 29 - 43.1]) compared to SAV (25.2% [95% CI: 19.9 - 31.3])(p=0.012). Long-term and mid-term follow-up in these studies showed moderate to severe AR was present in 24.1% and 28.1% of BAV and SAV patients, respectively. Conclusions: Notwithstanding publication bias, both survival rates and development of late AR following BAV and SAV are similar. However, reintervention rates are significantly higher following BAV compared to SAV.

scholarly journals Presence of mitral stenosis is a risk factor of new development of acute decompensated heart failure early after transcatheter aortic valve implantation

Open Heart ◽  
2020 ◽  
Vol 7 (2) ◽  
pp. e001348
Author(s):  
Tsukasa Okai ◽  
Kazuki Mizutani ◽  
Masahiko Hara ◽  
Tomohiro Yamaguchi ◽  
Mana Ogawa ◽  
...  
Keyword(s):  
Heart Failure ◽  
Aortic Valve ◽  
Acute Decompensated Heart Failure ◽  
Decompensated Heart Failure ◽  
Transcatheter Aortic Valve ◽  
New Development ◽  
Clinical Indices ◽  
Aortic Valve Implantation ◽  
Valve Implantation ◽  
Valve Pressure

AimsAcute decompensated heart failure (ADHF) can occur early after transcatheter aortic valve implantation (TAVI), but the risk factors or mechanisms associated with it have not been fully determined. This hypothesis-generating study aimed to investigate the clinical indices associated with the development of ADHF within 72 hours after TAVI and to improve procedural approaches for TAVI.Method and resultsIn this single-centre hypothesis generating prospective observational study, we enrolled 156 consecutive patients with severe aortic stenosis who underwent TAVI between January 2016 and February 2018 at our institution. We set the primary endpoint as the new development of ADHF within 72 hours after TAVI, and clinical indices associated with it were evaluated using a multivariable logistic model. The median age of the patients was 83 (quartile range 80–86) years, 48 (30.8%) were men and the median Society of Thoracic Surgery-Predicted Risk of Mortality was 7.1 (range 5.2–10.4). Mitral stenosis (MS), defined as mean transmitral valve pressure gradient ≥5 mm Hg, was present in 15 (9.6%) patients. After TAVI, the invasive mean transaortic valve pressure gradient (mAVPG) decreased from 48 (36–66) to 7 (5–11) mm Hg, and 12 (7.7%) patients developed ADHF within 72 hours after TAVI. Multivariable logistic regression analysis showed that MS (adjusted OR, 14.227; 95% CI 2.654 to 86.698; p=0.002) and greater decreases in mAVPG (1.038; 1.003 to 1.080; p=0.044) were associated with ADHF.ConclusionsMS and drastic improvement of mAVPG were associated with new development of ADHF within 72 hours after TAVI.

Sign in / Sign up

Export Citation Format

Share Document